These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 22106579)

  • 1. The Health Impact Fund: a potential solution to inequity in global drug access.
    Banerjee A; Pogge T
    Indian J Med Ethics; 2010; 7(4):240-3. PubMed ID: 22106579
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Introduction: pharmaceutical innovation: law & the public's health.
    Outterson K
    J Law Med Ethics; 2009; 37(2):173-5. PubMed ID: 19493064
    [No Abstract]   [Full Text] [Related]  

  • 3. Global pharmaceutical development and access: critical issues of ethics and equity.
    Lage A
    MEDICC Rev; 2011 Jul; 13(3):16-22. PubMed ID: 21778954
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Orphan economics: the downside of supplyside pharmacology.
    Samson K
    Ann Neurol; 2008 Sep; 64(3):A13-6. PubMed ID: 18825669
    [No Abstract]   [Full Text] [Related]  

  • 5. Pharmaceutical companies and global lack of access to medicines: strengthening accountability under the right to health.
    Grover A; Citro B; Mankad M; Lander F
    J Law Med Ethics; 2012; 40(2):234-50. PubMed ID: 22789043
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Industry, Academia and Government Partnership through the Global Health Innovative Technology Fund (GHIT)].
    Hinoshita E
    Yakugaku Zasshi; 2016; 136(2):237-42. PubMed ID: 26831799
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A new era of hope for the world's most neglected diseases.
    The
    PLoS Med; 2005 Sep; 2(9):e323. PubMed ID: 16138790
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Poverty, health & intellectual property rights with special reference to India.
    Satyanarayana K; Srivastava S
    Indian J Med Res; 2007 Oct; 126(4):390-406. PubMed ID: 18032814
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Assessing 15 proposals for promoting innovation and access to medicines globally.
    Hoffman SJ; So K;
    Ann Glob Health; 2014; 80(6):432-43. PubMed ID: 25960092
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Health Impact Fund: incentives for improving access to medicines.
    Banerjee A; Hollis A; Pogge T
    Lancet; 2010 Jan; 375(9709):166-9. PubMed ID: 20109894
    [No Abstract]   [Full Text] [Related]  

  • 11. Patents and access to drugs in developing countries: an ethical analysis.
    Sterckx S
    Dev World Bioeth; 2004 May; 4(1):58-75. PubMed ID: 15086374
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Can International Patent Law Help Mitigate Cancer Inequity in LMICs?
    Ragavan S; Vanni A
    AMA J Ethics; 2020 Feb; 22(2):E102-111. PubMed ID: 32048580
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Access to essential medicines: a Hobbesian social contract approach.
    Ashcroft RE
    Dev World Bioeth; 2005 May; 5(2):121-41. PubMed ID: 15842722
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Developing drugs for developing countries.
    Ridley DB; Grabowski HG; Moe JL
    Health Aff (Millwood); 2006; 25(2):313-24. PubMed ID: 16522573
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Developing medicines in line with global public health needs: the role of the World Health Organization.
    Pang T
    Camb Q Healthc Ethics; 2011 Apr; 20(2):290-7. PubMed ID: 21435304
    [No Abstract]   [Full Text] [Related]  

  • 16. Improving access to medicines in poor countries: the role of universities.
    Chokshi DA
    PLoS Med; 2006 Apr; 3(6):e136. PubMed ID: 16608382
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Global health impact: a basis for labeling and licensing campaigns?
    Hassoun N
    Dev World Bioeth; 2012 Dec; 12(3):121-34. PubMed ID: 22314005
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Patents and the obligation to protect health: examining the significance of human rights considerations in the protection of pharmaceutical patents.
    Owoeye OA
    J Law Med; 2014 Jun; 21(4):900-19. PubMed ID: 25087369
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comment: compulsory licensing of patented pharmaceutical inventions: evaluating the options.
    Reichman JH
    J Law Med Ethics; 2009; 37(2):247-63. PubMed ID: 19493070
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Drug resistance, patent resistance: Indian pharmaceuticals and the impact of a new patent regime.
    Halliburton M
    Glob Public Health; 2009; 4(6):515-27. PubMed ID: 19548158
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.